Quotient Sciences Constructs State-of-the-Art Early-Phase Formulation and Manufacturing Facility in U.S.
Quotient Sciences, announces a significant expansion to its operations in the U.S. with the opening of a state-of-the-art, 45,000-square-foot facility located near Philadelphia, in Garnet Valley, Pa. The $15 million investment will create a center of excellence for early-phase formulation development and clinical trial manufacturing.
Quotient Sciences is delighted to be taking part in the MHRA / HRA Combined Ways of Working Pilot
We are delighted to be taking part in the MHRA / HRA Combined Ways of Working Pilot and on Friday 22 June 2018 made its first two pilot Phase I submissions.
Arcinova, a Quotient Sciences business, increases GC-MS/MS capabilities with new system
Arcinova, a Quotient Sciences business, increase GC-MS/MS capabilities with purchase of new Thermo Scientific TSQ Duo triple quadrupole.
Pharmaterials rebrands to Quotient Sciences
Quotient Sciences announces that it has completed the integration and rebrand of Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K.
Quotient Sciences and PPD Form Innovative Partnership to Accelerate Pediatric Drug Development
The collaboration simplifies contracting and delivery by offering clients a single solution for an entire pediatric program, with only one contract and one PPD point of contact. As a result of that structure, the number of handoffs is significantly reduced and the process is much more streamlined, eliminating the delays that often occur when moving from early dosing to later phases.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing Organization
Quotient Sciences announces it has acquired Pharmaterials, a CDMO based in Reading, UK. The acquisition strengthens and expands Quotient’s formulation and manufacturing services footprint and further supports the growth of Quotient’s Translational Pharmaceutics platform.